Anti-inflammatory properties of cannabidiol, a nonpsychotropic cannabinoid, in experimental allergic contact dermatitis

Journal of Pharmacology and Experimental Therapeutics

Volumn 365, Issue 3, 2018, Pages 652-663

  Petrosino, Stefania ^a,b   Verde, Roberta ^a   Vaia, Massimo ^c   Allará, Marco ^a,b   Iuvone, Teresa ^c   Di Marzo, Vincenzo ^a  

^a CNR   (Italy)

^b Scientific Information and Documentation Center Epitech Group Srl   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 5' IODORESINIFERATOXIN; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CANNABICHROMENE; CANNABIDIOL; CANNABIDIVARIN; CANNABIGEROL; CANNABIGEVARIN; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 2; N OLEOYLETHANOLAMINE; PALMIDROL; POLYINOSINIC POLYCYTIDYLIC ACID; TETRAHYDROCANNABIVARIN; TETRAHYDROCANNABIVARINIC ACID; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; AMIDE; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID DERIVATIVE; CCL8 PROTEIN, HUMAN; ENDOCANNABINOID; INTERLEUKIN 6;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; HACAT CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; REGULATORY MECHANISM; SENSITIZATION; SKIN ALLERGY; CELL LINE; METABOLISM;

ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACIDS; CANNABIDIOL; CELL LINE; CHEMOKINE CCL8; DERMATITIS, ALLERGIC CONTACT; ENDOCANNABINOIDS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; POLYUNSATURATED ALKAMIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85047210703     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.117.244368     Document Type: Article

References (43)

1. Arnold JC, Hone P, Holland ML, and Allen JD (2012) CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells. Pharmacol Rep 64:751–757.
2. Bánvölgyi A, Pálinkás L, Berki T, Clark N, Grant AD, Helyes Z, Pozsgai G, Szolc-sányi J, Brain SD, and Pintér E (2005) Evidence for a novel protective role of the vanilloid TRPV1 receptor in a cutaneous contact allergic dermatitis model. J Neuroimmunol 169:86–96.
3. Barker JN (1992) Role of keratinocytes in allergic contact dermatitis. Contact Dermat 26:145–148.
4. Becker D and Knop J (1993) Mechanism in allergic contact dermatitis. Exp Dermatol 2:63–69.
5. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, and Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845–852.
6. Bisogno T, Sepe N, Melck D, Maurelli S, De Petrocellis L, and Di Marzo V (1997) Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J 322: 671–677.
7. Burstein S (2015) Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem 23:1377–1385.
8. Burstein SH and Zurier RB (2009) Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J 11:109–119.
9. Cantarella G, Scollo M, Lempereur L, Saccani-Jotti G, Basile F, and Bernardini R (2011) Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem Pharmacol 82:380–388.
10. Costa B, Giagnoni G, Franke C, Trovato AE, and Colleoni M (2004) Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 143:247–250.
11. de Paulis A, Annunziato F, Di Gioia L, Romagnani S, Carfora M, Beltrame C, Marone G, and Romagnani P (2001) Expression of the chemokine receptor CCR3 on human mast cells. Int Arch Allergy Immunol 124:146–150.
12. De Petrocellis L, Davis JB, and Di Marzo V (2001) Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett 506: 253–256.
13. De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, Stott CG, and Di Marzo V (2011) Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163:1479–1494.
14. Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, et al. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822–825.
15. Enk AH and Katz SI (1992) Early events in the induction phase of contact sensitivity. J Invest Dermatol 99:39S–41S.
16. Gaffal E, Cron M, Glodde N, and Tüting T (2013) Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors. Allergy 68:994–1000.
17. Iannotti FA, Di Marzo V, and Petrosino S (2016) Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. Prog Lipid Res 62:107–128.
18. Iannotti FA, Hill CL, Leo A, Alhusaini A, Soubrane C, Mazzarella E, Russo E, Whalley BJ, Di Marzo V, and Stephens GJ (2014) Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci 5: 1131–1141.
19. Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, Starowicz K, Steuder R, Schlicker E, Cravatt B, et al. (2007) Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 316:1494–1497.
20. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, and Koethe D (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94.
21. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, and Piomelli D (2005) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67: 15–19.
22. Maione S, Piscitelli F, Gatta L, Vita D, De Petrocellis L, Palazzo E, de Novellis V, and Di Marzo V (2011) Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br J Pharmacol 162:584–596.
23. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgänsberger W, et al. (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530–534.
24. Montecucco F, Bondarenko AI, Lenglet S, Burger F, Piscitelli F, Carbone F, Roth A, Liberale L, Dallegri F, Brandt KJ, et al. (2016) Treatment with the GPR55 antagonist CID16020046 increases neutrophil activation in mouse atherogenesis. Thromb Haemost 116:987–997.
25. Oka S, Wakui J, Ikeda S, Yanagimoto S, Kishimoto S, Gokoh M, Nasui M, and Sugiura T (2006) Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice. J Immunol 177:8796–8805.
26. Pazos MR, Mohammed N, Lafuente H, Santos M, Martínez-Pinilla E, Moreno E, Valdizan E, Romero J, Pazos A, Franco R, et al. (2013) Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. Neuropharmacology 71:282–291.
27. Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahy-drocannabivarin. Br J Pharmacol 153:199–215.
28. Pertwee RG (2015) Endocannabinoids and their pharmacological actions. Handb Exp Pharmacol 231:1–37.
29. Petrosino S, Cristino L, Karsak M, Gaffal E, Ueda N, Tüting T, Bisogno T, De Filippis D, D’Amico A, Saturnino C, et al. (2010) Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy 65:698–711.
30. Petrosino S and Di Marzo V (2017) The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol 174:1349–1365.
31. Petrosino S, Schiano Moriello A, Cerrato S, Fusco M, Puigdemont A, De Petrocellis L, and Di Marzo V (2016) The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels. Br J Pharmacol 173:1154–1162.
32. Russo EB, Burnett A, Hall B, and Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30:1037–1043.
33. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, and Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092–1101.
34. 2receptors. Biochem Pharmacol 120:63–71.
35. Slominski A, Pisarchik A, Zbytek B, Tobin DJ, Kauser S, and Wortsman J (2003) Functional activity of serotoninergic and melatoninergic systems expressed in the skin. J Cell Physiol 196:144–153.
36. Stanley CP, Hind WH, Tufarelli C, and O’Sullivan SE (2015) Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation. Cardiovasc Res 107:568–578.
37. Taub DD, Proost P, Murphy WJ, Anver M, Longo DL, van Damme J, and Oppenheim JJ (1995) Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest 95:1370–1376.
38. Ueda Y, Miyagawa N, Matsui T, Kaya T, and Iwamura H (2005) Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. Eur J Pharmacol 520:164–171.
39. Vaia M, Petrosino S, De Filippis D, Negro L, Guarino A, Carnuccio R, Di Marzo V, and Iuvone T (2016) Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis. Eur J Pharmacol 791:669–674.
40. van Loveren H, Meade R, and Askenase PW (1983) An early component of delayed-type hypersensitivity mediated by T cells and mast cells. J Exp Med 157:1604–1617.
41. Watanabe H, Unger M, Tuvel B, Wang B, and Sauder DN (2002) Contact hypersensitivity: the mechanism of immune responses and T cell balance. J Interferon Cytokine Res 22:407–412.
42. Xie J, Xiao D, Xu Y, Zhao J, Jiang L, Hu X, Zhang Y, and Yu L (2016) Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2. Oncotarget 7:6436–6447.
43. Yang L, Li FF, Han YC, Jia B, and Ding Y (2015) Cannabinoid receptor CB2 is involved in tetrahydrocannabinol-induced anti-inflammation against lipopolysac-charide in MG-63 cells. Mediators Inflamm 2015:362126.